B.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...
B.Riley Financial Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...